Healthcare priorities entangled in packed Congress agenda

The congressional to-do list for December is quite long, with the Senate looking to pass major tax overhaul and the looming threat of a government shutdown. Most important for the healthcare industry is the fact that the Affordable Care Act (ACA) and the Children’s Health Insurance Program (CHIP) have become one of the many items fighting for attention on Capitol Hill.

As POLITICO reports, the tax bill already has major implications for healthcare programs. Senate Republicans have included a repeal of the ACA’s individual mandate in order to bank on its $300 billion in deficit reductions for other tax cuts. The move could stir up hard feelings left over from the repeal-and-replace battles from earlier in the year.

Additionally, the bill would trigger billions of dollars in cuts to Medicare, according to the Congressional Budget Office.

Complicating the debate over the tax bill is a Dec. 8 deadline to pass a federal spending bill or, more likely, a short-term continuing resolution to avoid a government shutdown. An end-of-year spending deal could include a short-term stabilization measure for the ACA exchanges, as proposed by Sens. Lamar Alexander, R-Tennessee, and Patty Murray, D-Washington, which may fund the law’s cost-sharing reduction subsidies for insurers.

The spending package may also reauthorize CHIP, which was allowed to expire at the end of September. Several states have said they’ll be out of CHIP funds sometime in January without congressional action.

Read more about the political and legislative factors complicating the end-of-year healthcare agenda by clicking on the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.